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Abstract: Crohn’s disease (CD) is a chronic, relapsing disease, the continuous cycle of which 
deeply affects the long-term course which, eventually, leads to ﬁ  brosis and development of 
transmural complications. It is well known that CD is an immune-mediated clinical condition 
and that tumor necrosis factor-α (TNF-α) plays a fundamental role in the pathogenesis of the 
disease. Current clinical guidelines recommend that patients with mild to moderate active CD 
should be treated initially with corticosteroids. Although this approach is effective in inducing 
remission, some patients may become dependent on, or refractory to, these drugs in the long 
term, thus increasing the risk of developing steroid-related adverse effects. A recent Cochrane 
systematic review established that inﬂ  iximab (IFX) is effective in inducing remission in patients 
with CD. Although only a few published studies have assessed IFX for the maintenance of 
remission in the long term, there is evidence that IFX is superior to placebo in sustaining clinical 
remission and ﬁ  stula healing; moreover, corticosteroid-sparing effects have been demonstrated. 
IFX is associated with the formation of antibodies to IFX which can lead to infusion reactions 
and shorter duration of response, but when comparing episodic vs scheduled maintenance treat-
ment, the latter appears to sensibly reduce immunogenicity, thus offering improved efﬁ  cacy 
and tolerance. The ﬁ  nal point to consider is the best time to introduce IFX in the therapeutic 
algorithm of CD. Early use of IFX has been suggested to be more effective than late, and may 
potentially change the natural history of the disease. Effective induction and maintenance 
therapy with IFX is the only means with which to maintain long-lasting clinical and mucosal 
remission which, in turn, may modify the long-term course of the disease. Furthermore, when 
treating inﬂ  ammatory bowel disease patients with IFX, an appropriate risk-beneﬁ  t balance has 
to be taken into consideration, because the precise risk of serious adverse events associated 
with anti-TNF treatment in CD remains to be fully elucidated.
Keywords: inﬂ  ammatory bowel disease, Crohn’s disease, inﬂ  iximab therapy, steroid sparing, 
tumor necrosis factor-α
Introduction
Crohn’s disease (CD), an inﬂ  ammatory disorder which can involve any part of the 
gastrointestinal tract, is characterized by transmural damage of the bowel wall.1 The 
incidence of CD is approximately 5 to 10 new cases per 100,000 individuals/year.2 
However, the incidence has been progressively increasing in Europe and North 
America. Estimated CD prevalence in North America ranges from 26.0 to 198.5 cases 
per 100,000 persons, which means 400,000 to 600,000 CD patients in North America 
alone.3,4 The pathogenesis of CD remains to be fully elucidated, but it is presumed to 
occur through a combination of three essential co-factors: host susceptibility, intestinal 
microﬂ  ora, and mucosal immunity, the combined effect of which is sustained activa-
tion and uncontrolled response of the mucosal immune system against the normal 
commensal microbiota.5 In normal conditions, the mucosal immune system is in a 
constant state of “controlled inﬂ  ammation”. Homeostasis is achieved by a balance 
between T cell activation after antigen presentation and apoptosis.6 CD4 + T-helper 1 Biologics: Targets & Therapy 2009:3 40
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(Th 1) lymphocytes from patients with CD are resistant to the 
induction of apoptosis by a variety of stimuli.5 Moreover, the 
excessive activation of mucosal T cells, which is ampliﬁ  ed 
and perpetuated by the increased release of pro-inﬂ  ammatory 
cytokines, such as interferon γ, tumor necrosis factor-α 
(TNF-α) and interleukin-12, by the intestinal lamina propria 
mononuclear cells, leads to transmural tissue damage, which 
is the pathologic characteristic of CD.7 The pro-inﬂ  ammatory 
cytokine TNF-α, appears to play a pivotal role in the patho-
genesis of mucosal inﬂ  ammation, mediating the inﬂ  ammatory 
cascade in CD.8 TNF-α is mainly produced by monocytes 
and macrophages, although many other cells of the innate 
and adaptive immune system produce signiﬁ  cant amounts of 
this cytokine;8 moreover, several studies have demonstrated 
increased concentrations of TNF-α in blood, mucosa and stool 
from CD patients, thus making TNF-α a rational target in the 
treatment of active CD.9 In many patients, CD may be refrac-
tory to conventional treatment such as corticosteroids, enteral 
nutrition and immunomodulators (eg, azathioprine [AZA], 
6-mercaptopurine [6-MP] and methotrexate [MTX]);10,11 on 
a long-term basis, some patients may become dependent 
on corticosteroids, thus increasing the risk of developing 
steroid-related adverse effects.12 Moreover, as shown by 
Cosnes et al, despite the increased use of immunosuppres-
sants over the years, the need for surgical intervention in CD 
patients has remained high over the past few decades.13 In 
these clinical situations, it is important that other treatment 
options be considered. Over recent years, a growing number 
of reports have suggested that TNF-α blocking agents may be 
effective for inducing and mainting remission in CD. Many 
biologic compounds targeting TNF-α have been developed: 
the monoclonal antibody inﬂ  iximab (IFX), a chimeric mouse/
human immunoglobulin (Ig) G1 anti-TNF-α, was the ﬁ  rst 
biologic agent to be used in the treatment of inﬂ  ammatory 
bowel disease; the fully human IgG1 antibody adalimumab; 
the humanized Fab antibody fragment CDP-870; and etan-
ercept and onercept, TNF-α receptor fusion proteins that 
bind to two speciﬁ  c transmembrane receptors of TNF-α 
(P75 and P55).14,15 Short-term studies have shown that use 
of these biologic compounds results in less need for surgical 
treatment and may alter the natural history of the disease 
through their ability to induce mucosal healing.16,17 Although 
IFX and adalimumab have been proven to be effective for 
1-year maintenance of steroid-free remission in patients 
with CD who respond to induction therapy, available clini-
cal data for certolizumab pegol showed a signiﬁ  cant rate of 
response and remission at week 26, only. Currently, the US 
Food and Drug Administration (FDA) approves all three 
biologic compounds for the treatment of CD, and the European 
Medicines Agency (EMEA) approves IFX and adalimumab 
but not certolizumab pegol. IFX was the ﬁ  rst biologic com-
pound to be used in the treatment of moderate to severe active 
CD and, therefore, most of the clinical experience on anti-TNF 
drugs in CD comes from this drug. Although the efﬁ  cacy of 
a therapeutic strategy consisting of a loading dose of 3 IFX 
infusions and, thereafter, every 8 weeks, is supported by sev-
eral placebo-controlled studies, very few data are available on 
the use of IFX for  12 months or  8 doses in active CD.16,18 
The present review summarizes clinical data on long-term 
IFX treatment in CD. The literature search focused on papers 
published from 1999 to 2008. Abstracts from congress pro-
ceedings (Digestive Disease Week [DDW] United European 
Gastroenterology Week [UEGW] and European Crohn’s and 
Colitis Organization [ECCO]) were also included.
Inﬂ  iximab
Structure and complex 
formation with TNF
TNF-α originates as a membrane-anchored precursor (pro-
TNF) which is cleaved by the metalloproteinase TNF-α-
converting enzyme (TACE), to then be secreted as a 17-kDa 
soluble protein. TNF-α exerts its effects through binding 
either one of the TNF-α receptors (TNFRs), TNFR1 or 
TNFR2.19 IFX is a chimeric monoclonal Ig G1 (75% human 
and 25% murine) anti-TNF-α. IFX is able to bind soluble 
and membrane-bound TNF, and in vitro data suggest that it 
can induce T-cell apoptosis via complement activation or 
antibody-dependent cell cytotoxicity.19 Besides its action on 
immune and epithelial cells, TNF-α plays a crucial role in 
regulating cell adhesion molecule expression by intestinal 
endothelium and ﬁ  broblasts. Danese et al recently reported 
that CD patients undergoing IFX treatment down-regulate 
the expression levels of the vascular cell adhesion molecule 
(VCAM-1) and CD40 on the intestinal mucosal endothe-
lium, thus inhibiting T-cell recruitment.20 In addition to 
TNF-α blockade and apoptosis induction, IFX exerts a wide 
spectrum of anti-inﬂ  ammatory activities. For instance, IFX 
reduces the circulating levels of basic ﬁ  broblast growth fac-
tor (bFGF) and vascular endothelial growth factor (VEGF).21 
These two cytokines, proposed as markers of ﬁ  brosis and 
angiogenesis, are typically over-expressed in CD.
Efﬁ  cacy proﬁ  le of long-term 
use of IFX in CD
At present, biologic therapy with IFX is used in CD 
patients with ﬁ  stulizing disease or who have not shown Biologics: Targets & Therapy 2009:3 41
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a good response to conventional agents. These include 
corticosteroid-dependent patients and/or those unresponsive/
intolerant to immunosuppressants (AZA/6-MP and MTX). 
Several randomized clinical trials (RCTs) have shown that 
IFX is effective in the treatment of clinically active CD 
patients, showing excellent results at short-term evalua-
tion.16,17 However, although many CD patients have been 
treated with IFX on a long-term basis, to date only 4 RCTs 
evaluating IFX for the maintenance of remission in CD 
patients have been published (Table 1).22–25 In 1999, Rutgeerts 
et al published the results of the ﬁ  rst RCT aimed at evaluat-
ing the efﬁ  cacy and safety of repeated infusions with IFX 10 
mg/kg in patients showing a clinical response to an initial 
dose of IFX.22 The 73 patients enrolled with moderate to 
severe CD came from a cohort of patients who had shown a 
clinical response to IFX at 4 weeks in the earlier study of 
Targan et al26 All patients, received 4 scheduled infusions 
every 8 weeks and were evaluated for efﬁ  cacy and safety at 
4-week intervals. At week 44, 8 weeks after the last infusion, 
52.9% of the IFX-treated patients were in remission with 
only 20.0% of placebo (p = 0.013). The ACCENT I trial (A 
Crohn’s disease Clinical trial Evaluating IFX in a New long-
term Treatment regimen) was the largest randomized, con-
trolled clinical study designed to assess the efﬁ  cacy of 
repeated infusions (on scheduled timing) of IFX in patients 
who had shown an initial response after the ﬁ  rst infusion.23 
Of the 580 patients enrolled with moderate to severe CD 
(Crohn’s disease activity index [CDAI] between 220 and 
440), 573 patients were started on IFX 5 mg/kg; 335 (58%) 
were responders at week 2. The 335 responders were then 
randomized to receive placebo, 5 mg/kg maintenance regi-
men, or 10 mg/kg maintenance regimen. At week 54, 
approximately 3 times as many patients (29% vs 9%) on IFX 
vs placebo had maintained clinical remission. This study 
showed for the ﬁ  rst time that the beneﬁ  ts of IFX in CD could 
be maintained, over the long term in patients treated with 
systematic maintenance therapy. In order to evaluate the 
efﬁ  cacy of regularly scheduled retreatment vs episodic retreat-
ment with IFX for maintenance of remission in patients with 
CD, Rutgeerts et al performed a post hoc analysis on all 
patients who entered the ACCENT I study.27 This study 
evaluated the impact of the different treatment strategies on 
important outcome data such as mucosal healing, hospitaliza-
tions, and surgery. The results showed that regularly scheduled 
treatment with 5 mg/kg and 10 mg/kg IFX led to a statistically 
signiﬁ  cant (p   0.05) higher proportion of patients in remis-
sion at weeks 10, 14, 22, and 46 compared with the episodic 
treatment group. Furthermore, 44% of patients in the regularly 
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scheduled treatment groups had mucosal healing at week 54 
compared with 18% in the episodic treatment group 
(p   0.014). Moreover, fewer CD-related hospitalizations 
occurred over the 54-week period in patients undergoing 
systematic maintenance therapy (24 events per 100 patients) 
than in patients treated episodically (38 events per 100 patients; 
p = 0.023). Only one randomized, double-blind, controlled 
study evaluated the long-term efﬁ  cacy of IFX as mainte-
nance treatment in patients with fistulizing CD. In the 
ACCENT II trial, 306 patients affected by ﬁ  stulizing CD 
were initially treated with IFX 5 mg/kg at weeks 0, 2, and 6, 
and responders were subsequently randomized to placebo or 
IFX 5 mg/kg at 8-week intervals until the end of the study 
at week 54.24 At week 14, of 306 patients, 195 (69%) showed 
a response to the IFX induction therapy with closure of at 
least 50% of the ﬁ  stulas. At week 54, 39% of patients receiv-
ing maintenance IFX 5 mg/kg every 8 weeks and 19% of 
patients receiving placebo demonstrated complete closure 
of all ﬁ  stulas (p   0.009). In a smaller, prospective, non-
controlled study, Domènech et al evaluated the clinical 
outcome of CD after induction of remission with 3 IFX infu-
sions (23 patients with luminal disease) and after maintenance 
of remission with a 1-year course of IFX every 8 weeks 
(27 patients with luminal and perianal disease).28 After the 
induction regimen, only 5 patients had a partial response and 
all relapsed in the ﬁ  rst 2 months after the third IFX infusion. 
Among those patients with a complete response (18/23), after 
the induction treatment, 10 patients were observed at follow-
up, with a median time of 33 months (range 8–54), and only 
one of them relapsed during this period (at 44 months). Only 
5 out of 18 (27.7%) patients who achieved complete remis-
sion relapsed within the ﬁ  rst 6 months of follow-up. In 
contrast, early relapse in perianal disease was observed after 
drug withdrawal, even in patients with a long-term complete 
response while on IFX. Of the 14 patients with ﬁ  stulizing 
CD who underwent a long-term scheduled regimen, 9 (64%) 
relapsed after a mean time of 5.2 ± 5.5 months (range 2–18). 
A retrospective analysis of data on the efﬁ  cacy of long-term 
therapy with IFX in CD patients treated with a scheduled 
regimen has recently been published (Table 1).29 The medical 
charts of 50 patients (40 CD) who, after a loading dose of 
3 IFX infusions, received scheduled retreatment every 
8 weeks as maintenance protocol, were reviewed. In CD 
patients, median duration of treatment was 27 (range 4–64) 
months. Overall, 32 (80%) CD patients showed a sustained 
clinical response or remission throughout the maintenance 
period. Three CD patients shortened the interval between 
infusions. Eight (20%) CD patients underwent surgery on 
account of disease ﬂ  are-up. Nine out of 29 CD patients who 
discontinued scheduled IFX treatment were still relapse-free 
after a median of 16 (range, 5–30) months after the last infu-
sion. Recently, at the 3rd European Crohn’s and Colitis 
Organisation Meeting, Schnitzler et al presented a retrospec-
tive analysis on a series of 614 consecutive CD patients 
treated long term with IFX, with a median follow-up of 55 
(interquartile range [IQR] 27–83) months.30 Scheduled treat-
ment was associated with less need for hospitalization 
(50/194, 26%, median hospitalization 1 [IQR 1–2], median 
follow-up 1.91 years [IQR 0.92–3.42]) with respect to the 
episodic strategy (165/353, 47%, median hospitalization 2 
[IQR 1–4], median follow-up 6.05 years [IQR 4.24–7.27]) 
(p   0.0001); moreover, patients on a scheduled regimen 
from the start had a signiﬁ  cantly better outcome than patients 
initially treated episodically (log rank: p   0.0001). An 
important issue concerns the association of immunosuppres-
sive drugs (AZA or MTX) in combination with IFX treat-
ment. Although several published studies have addressed 
this topic, they show conﬂ  icting results. Lémann et al pub-
lished results of an RCT carried out in order to evaluate the 
usefulness of IFX induction treatment combined with AZA 
or 6-MP, in steroid-dependent CD patients.31 Out of 113 CD 
patients, 57 were randomized to receive IFX 5 mg/kg and 58 
to receive placebo at weeks 0, 2, and 6. A larger number of 
patients were in steroid-free remission at week 24 in the IFX 
group than in the placebo group (57% vs 29%; p = 0.003). 
At 56 weeks’ follow-up, a similar trend was observed with 
a remission rate of 40% in IFX/AZA or 6-MP-treated patients 
compared to 22% placebo/AZA or 6-MP-treated patients 
(p = 0.04). Van Assche et al evaluated the inﬂ  uence of dis-
continuation of immunosuppressives in CD patients in clinical 
remission with combination therapy (IFX plus AZA).32 Eighty 
patients were randomized either to continuation (N = 40) or 
to withdrawal (N = 40) of immunosuppressives, while all 
patients were on scheduled IFX maintenance treatment. When 
estimating the need to shorten the IFX dose intervals, no dif-
ference was found between the two groups of patients (60% 
[95% CI: 45%–74%] vs 55% [95% CI: 40%–69%], p = 0.65). 
C-reactive protein (CRP) levels from week 8 through week 
104 were signiﬁ  cantly higher in the discontinuation group 
(median 2.8, IQR: 1.0–8.0) than in the continuation group 
(median 1.6, IQR: 1.0–5.6, p   0.005). IFX trough levels 
from week 8 through week 54 were signiﬁ  cantly higher in 
the continuation group than in the discontinuation group 
(median [IQR]: 2.87 [1.42–4.80] vs 1.65 [0.54–3.53] μg/mL, 
p   0.0001). The authors concluded that combined IFX and 
immunosuppressive treatment was not more efﬁ  cacious than Biologics: Targets & Therapy 2009:3 43
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IFX monotherapy despite the finding of higher IFX 
concentrations and lower CRP levels in the combination 
regimen. On the contrary, at the 16th UEGW, Colombel et al 
presented the results of the SONIC (Study of Immuno-
modulator Naive patients in Crohn’s Disease) trial, aimed at 
evaluating the efﬁ  cacy of IFX vs AZA alone and vs the 
combination of both drugs, demonstrating the clear superior-
ity of the combined treatment.33 This large multicenter study 
was carried out in more than 200 sites in the US, Israel, and 
Europe and comprised 508 patients naïve to both biologics 
and immunomodulators. The primary endpoint was steroid-
free remission at week 26 and the secondary endpoint was 
endoscopic healing at week 56. At week 26, patients receiv-
ing IFX in combination with AZA showed the highest rate 
of remission (57%) compared with IFX alone (44%) or AZA 
alone (30%). Considering mucosal healing at week 56, 
endoscopic remission rates paralleled clinical remission rates 
in that patients on combination therapy scored the best, while 
those receiving IFX alone or AZA alone were second and 
third, respectively. If these data are conﬁ  rmed in a full paper, 
they will have deﬁ  nite implications at least for the naïve 
patients, having shown that the early use of the combined 
treatment could be effective in decreasing short- and long-
term complications such as surgery and hospitalizations. An 
interesting issue that should be taken into consideration is 
the effectiveness of early use of biologic therapy with 
combined immunosuppressants compared with conven-
tional management (eg, corticosteroids) in patients with 
active CD (ie, top-down vs step-up strategy). D’Haens et al 
have, indeed, reported data from a comparison of top-
down vs step-up therapy.34 The remission rate, deﬁ  ned as 
CDAI   150 without the use of steroids and without bowel 
resection, was signiﬁ  cantly higher in patients in the early 
combined immunosuppression group than in those receiv-
ing conventional treatment, both at week 26 (60% vs 36%, 
p = 0.0062) and at week 52 (61.5% vs 42.2%, p = 0.0278). 
The authors concluded that remission rates in patients who 
received early combined immunosuppression were higher 
than those in patients receiving only corticosteroids. 
Finally, Schnitzler et al presented the results of a retrospec-
tive analysis on 614 consecutive CD patients who underwent 
long-term IFX treatment over a median of 55 months follow-
up, in order to assess the magnitude of loss of response and 
how to maintain clinical response by shortening of the inter-
val between infusions, increasing dose of IFX, or a change 
from episodic to scheduled treatment every 8 weeks.35 
Reduction of the interval between infusions was necessary 
in 108 patients (19.7%), increase of the dose in 144 patients 
(26.3%), and increase of the dose plus a reduction of the 
interval in only 21 patients (3.8%). Overall, in the total cohort 
of initial responders, only 21.6% (n = 118) had to stop IFX 
treatment due to loss of response, despite interventions. The 
median time to switch to the every 8 weeks schedule in 
the episodic group was 26 months (IQR 12–47) and/or 
6 infusions (IQR 4–10). The authors concluded that ﬂ  exibility, 
both in dose and time-interval, may be useful to keep the 
disease under control in the long term. In conclusion, sched-
uled IFX treatment has proven to be an effective strategy in 
CD patients, for long-term maintenance of clinical remission; 
furthermore, long-lasting remission has been observed also 
after IFX withdrawal.
Steroid-sparing effect
For many years, corticosteroids have represented the stan-
dard therapy in inﬂ  ammatory bowel disease, having been 
demonstrated to be efﬁ  cacious in inducing a rapid clinical 
response, both in CD and ulcerative colitis; however, apart 
from their inability to maintain a long-lasting remission, 
the side effects after long-term use exceeded their clinical 
beneﬁ  ts. The steroid-sparing effect of IFX was another 
important ﬁ  nding emerging from several studies. In the 
ACCENT I trial, patients on maintenance IFX treatment were 
signiﬁ  cantly more likely to remain in steroid-free remission 
at 54 weeks compared to those who received a single dose 
of IFX and were on placebo maintenance treatment (29% 
vs 9%; p = 0.004).23 In a long-term IFX scheduled study, 
10/31 (32.2%) CD patients required concomitant steroid 
treatment during the maintenance period compared to 
25/31 (80.6%) patients on steroids at enrolment; moreover, 
in patients who were receiving corticosteroids, the median 
daily corticosteroid dose was reduced from 0.7 mg/kg/day at 
enrolment to 0.25 mg/kg/day.29 In the D’Haens et al study, 
which evaluated the long-term results of the two treatment 
strategies (top-down vs step-up approach), 17% of patients 
in the conventional management group (eg, corticosteroids, 
followed in sequence by AZA and IFX) were still receiving 
corticosteroids compared with none of the patients in the 
top-down group (IFX and AZA), at 12 months.34 These data 
conﬁ  rm the efﬁ  cacy of an IFX scheduled treatment regimen 
in avoiding the well-known morbidity associated with long-
term corticosteroid therapy.
Evidence of mucosal healing
ACCENT I was the ﬁ  rst study to evaluate the effectiveness 
of long-term IFX treatment in inducing mucosal healing. 
Rutgeerts et al performed an endoscopic sub-study of the Biologics: Targets & Therapy 2009:3 44
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ACCENT I population, evaluating the effects of IFX on 
mucosal inﬂ  ammation and mucosal healing.36 Endoscopic 
examinations were performed at baseline and at week 54. 
The authors showed that a signiﬁ  cantly higher proportion 
of week 2 responders in the scheduled maintenance group 
presented complete mucosal healing at week 54 compared 
with patients receiving the episodic treatment (50% vs 
7%, p = 0.007). A signiﬁ  cantly greater improvement in the 
Crohn’s Disease Endoscopic Index of Severity (CDEIS) 
score was observed with scheduled maintenance compared 
with episodic treatment at week 54 (p = 0.026). Some 
abstracts recently presented at the DDW 2008 conﬁ  rmed the 
effectiveness of long-term IFX treatment in inducing mucosal 
healing. In a long-term follow-up study by Schnitzler et al37 
614 consecutive CD patients underwent long-term treatment 
with IFX between 1995 and 2007, with a median follow-
up of 59 months; 8091 IFX infusions were administered. 
A total of 547 patients (89%) showed a short-term response. 
In 388 patients, endoscopy was performed within a median 
of 1.61 months prior to ﬁ  rst IFX infusion, and 263 patients 
with an initial response and further retreatment underwent 
endoscopy after a median of 11.05 months from starting IFX. 
In these patients, IFX treatment was scheduled in 33.5%, 
episodic in 24.7% and episodic with switch to maintenance 
in 41.8%. More than two thirds (64.1%) were under concomi-
tant immunomodulators and corticosteroids. Overall, 61.2% 
of the 263 initial responders (n = 161) showed mucosal heal-
ing, with 106 patients having full mucosal healing (40.3%) 
and 55 (20.9%) improvement in the CDEIS after a median 
of 4 IFX infusions. Patients on scheduled treatment from the 
start were more likely to show mucosal healing than patients 
who were started on episodic treatment (67/88 vs 94/175, 
respectively, p   0.0001, OR 2.75 [95% CI 1.55–4.88]). Of 
the patients showing sustained clinical beneﬁ  t until the end 
of follow-up, 65.9% presented mucosal healing compared to 
50% of patients (50/100) who withdrew from IFX due to loss 
of response or side effects (p   0.01). These results conﬁ  rm 
the advantages of early use of IFX in the healing of mucosal 
ulcerations and that scheduled IFX therapy is more likely 
to result in mucosal healing than episodic therapy. Baert 
et al reported the results of a study aimed at evaluating the 
relevance of mucosal healing in CD in order to predict the 
clinical outcome in the following 2 years.38 A total of 133 CD 
patients were randomized to treatment with combined immu-
nosuppression, namely IFX and AZA or corticosteroids. 
Of the 133 CD patients, 44 underwent ileocolonoscopy at 
2 years. The Simple Endoscopic Score for CD (SES-CD) was 
used to evaluate endoscopic CD activity. Data were available 
in 42/44 patients. A SES-CD score = 0 at year 2 predicted 
stable clinical remission in the following 2-year period in 
15/22 patients (68%) compared to 7/19 (35%) patients with 
endoscopic activity (SES-CD 2–9) (p = 0.004). These results 
provide evidence that complete mucosal healing signiﬁ  cantly 
increases clinical remission rates 2 years later. No signiﬁ  cant 
differences in the use of medication were observed between 
the two groups during years 3 to 4, probably due to the small 
number of patients studied (p = 0.27).
Issues requiring particular attention
Immunogenicity
The response of CD to IFX treatment is initially high. How-
ever, a loss of efﬁ  cacy over time is observed in some cases. 
Several potential mechanisms may account for the progres-
sive loss of response, among which the most important are 
drug-related mechanisms, including immunogenicity and 
tolerance to the drug. The development of antibodies against 
IFX may have a negative impact on the use of this compound 
in the clinical setting. Immunogenicity may be responsible 
for acute and delayed infusion reactions but may also cause 
a loss of clinical response. Baert et al in evaluating serum 
levels of antibodies to IFX (ATI) and correlating them with 
time to loss of response and infusion reactions39 (Table 2), 
found that concentrations of 8.0 μg/mL or greater before an 
infusion predicted a shorter duration of response (35 days 
vs 71 days in patients with concentrations  8.0 μg/mL; 
p   0.001) and a higher risk of infusion reactions (RR, 2.40; 
95% CI, 1.65–3.66; p   0.001). In the ACCENT I trial, ATI 
were found in 64 out of 442 (14%) patients: 41 (28%) patients 
in the episodic-treated group compared to 23 (15%) patients 
in the maintenance protocol (Table 2).23 The presence of ATI 
may also be correlated with infusion reaction; in fact, 38% of 
patients positive for antibodies to IFX had one or more infu-
sion reactions compared with 24% of patients negative for 
antibodies to IFX, but 16% of infusions were associated with 
an infusion reaction in the ATI-positive patients compared 
with 8% of infusions in the ATI-negative patients. When con-
sidering the efﬁ  cacy of the two treatment strategies (episodic 
vs scheduled), it should not be forgotten that intermittent or 
episodic dosing allows blood IFX concentrations to drop to 
undetectable levels while systematic scheduling regimens 
provide consistent therapeutic drug concentrations. Results 
emerging from the study by Hanauer et al demonstrated that 
the formation and concentrations of ATI were correlated 
with lower post-infusion serum IFX concentrations and with 
an increase in severe infusion reactions or serum sickness-
like reactions (Table 2).40 In this study, 573 CD patients Biologics: Targets & Therapy 2009:3 45
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received 5 mg/kg of IFX (week 0) and were then randomly 
assigned to placebo (group I), 5 mg/kg IFX at weeks 2 and 
6 and every 8 weeks thereafter until week 46 (group II), or 
5 mg/kg IFX at weeks 2 and 6, followed by 10 mg/kg there-
after (group III) as scheduled maintenance treatment. ATI 
were detected in 30%, 10% and 7% of groups I, II and III, 
respectively (p   0.0001). ATI were also associated with 
a 12% absolute increase in infusion reactions. The authors 
concluded that patients undergoing induction treatment 
followed by the scheduled maintenance regimen showed 
reduced ATI formation and a greater clinical beneﬁ  t com-
pared to those receiving a single dose followed by episodic 
retreatment. Similar results were reported by Maser et al who 
evaluated the effect of scheduled IFX infusion on antibody 
formation and their clinical signiﬁ  cance in CD patients.41 
ATI and trough serum IFX were measured in 105 patients 
with CD treated with IFX for induction of remission and 
followed by episodic retreatment (n = 23) or scheduled 
therapy at 6- to 8-week intervals (n = 82). ATI were present 
in 21% of patients, 25% of patients were ATI negative and 
54% were antibody inconclusive. Antibody formation was 
higher after episodic compared to scheduled treatment (39% 
vs 16%; p   0.036). In the 105 patients evaluated, a posi-
tive relationship was found between serum concentration of 
IFX and clinical remission interval (R2 = 0.61; p   0.001). 
The rate of clinical remission was higher in patients with 
a detectable trough serum IFX compared with patients in 
whom serum IFX was undetectable, including those without 
antibodies (82% vs 6%; p   0.001). Vermeire et al evalu-
ated whether the concomitant use of immunosuppressive 
therapy (AZA or MTX) could decrease ATI formation, thus 
reducing the negative impact that these have on the clini-
cal outcome (Table 2).42 Overall, 174 CD patients treated 
with IFX episodic schedule were prospectively evaluated. 
Patients were divided into 3 groups: no immunosuppressives 
(n = 59), concomitant MTX (n = 50), and concomitant AZA 
(n = 65). ATI and IFX concentrations were measured before 
and 4 weeks after each infusion. The authors detected ATI 
in 55% (96/174) of the patients. The concomitant use of 
immunosuppressive treatment was associated with a lower 
incidence of ATIs (53/115; 46%) compared with patients 
not on concomitant immunosuppressive therapy (43/59; 
73%; p   0.001). Patients not taking immunosuppressives 
had lower IFX levels (median 2.42 μg/mL) 4 weeks after 
follow-up infusion than patients taking concomitant immu-
nosuppressive therapy (median 6.45 μg/mL) (p = 0.065), but 
there was no difference between MTX and AZA. In patients 
who developed signiﬁ  cant ATI levels ( 8 μg/mL) during 
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follow-up, the IFX levels 4 weeks after the ﬁ  rst infusion 
were retrospectively found to be signiﬁ  cantly lower than in 
patients who did not develop ATI at follow-up.
Stenosis
Since CD is caused by a transmural inﬂ  ammatory process, 
leading to symptomatic stenosis, the differentiation between 
a prevalent inﬂ  ammatory and a ﬁ  bromatous process is often 
difﬁ  cult but is essential in order to adopt appropriate clinical 
management (ie, medical vs surgical treatment). Moreover, 
following reports of stricture and bowel obstruction occurring 
after IFX treatment, the concept that rapid mucosal healing 
with consequent excessive ﬁ  brogenesis, induced by this 
biologic agent, has given rise to concern that this treatment 
could lead to symptomatic intestinal stenosis, stricture, or 
obstruction (SSO).43,44 In order to shed further light on this 
issue, Lichtenstein et al analyzed data from the observa-
tional TREAT (Crohn’s Therapy, Resource, Evaluation, and 
Assessment Tool) Registry and ACCENT I study in order to 
establish whether IFX treatment could increase the risk of 
intestinal stenosis.45 In the TREAT registry, 3,179 patients 
with 5,621 patient/years (pt/y) of follow-up were on IFX 
treatment and 3,111 patients with 4,651 pt/y of follow-up 
on other CD treatments. The authors showed that duration, 
severity and localization of the disease (ileal disease only) 
were signiﬁ  cant predictors of symptomatic stenosis (hazard 
regression [HR] = 1.02, 95% CI 1.00–1.04, HR = 2.35, 95% 
CI 1.35–4.09, HR = 1.56, 95% CI 1.04–2.36, respectively) 
but, interestingly, new corticosteroid use (HR = 2.85, 95% 
CI 1.23–6.57) was a signiﬁ  cant predictor for stricture devel-
opment. When considering IFX treatment, symptomatic 
stenosis or obstruction occurred in 88 IFX-treated patients 
compared to 49 patients who received other treatments only 
(1.95 events/100 pt/y vs 0.99 events/100 pt/y, p   0.001, 
univariate regression analysis). But when data were adjusted 
for other factors, such as disease characteristics, neither 
previous nor new IFX use was signiﬁ  cantly associated with 
stenosis development (HR = 1.11, 95% CI 0.72–1.73 and 
HR = 1.65, 95% CI 0.74–3.70). Therefore, even if standard 
univariate analysis demonstrated a higher incidence of 
stricture development in IFX-treated patients, it is possible 
with multivariable analysis to separate the individual factor 
associated with development of SSO, thus suggesting that 
IFX treatment could have been proposed in CD patients with 
a more advanced stage of the disease, more likely presenting 
ﬁ  brostenotic disease per se. In the ACCENT I trial, a total 
of 573 patients were randomly assigned to receive either 
episodic treatment, or scheduled maintenance treatment with 
either IFX 5 mg/kg or 10 mg/kg. Symptomatic stenosis was 
reported in 12 (6.4%) patients who received episodic treat-
ment and in 10 (5.2%) and 13 (6.7%) patients who received 
5 mg/kg or 10 mg/kg IFX scheduled strategy, respectively 
(p   0.05). No increase in the occurrence or severity of 
stenosis was observed despite different IFX dose exposure. 
An interesting study by Di Sabatino et al attempted to ﬁ  nd a 
pathophysiologic explanation for the potential inﬂ  uence of 
IFX on intestinal ﬁ  brogenesis in CD, by measuring serum 
levels of bFGF and VEGF, two cytokines known to promote 
repair of tissue damaged by inﬂ  ammation, through modula-
tion of ﬁ  broblast proliferation.21 The authors evaluated serum 
levels of bFGF and VEGF in 22 CD patients, during and 
after 12 weeks of IFX treatment. Results showed that IFX 
can induce a reduction in serum bFGF and VEGF levels in 
almost all patients: bFGF (39.3 ± 13.2 vs 21.8 ± 7.1 pg/mL) 
and VEGF (1003 ± 227 vs 486 ± 180 pg/mL, p   0.001) 
levels 2 weeks after the ﬁ  rst infusion. Although these ﬁ  nd-
ings did not allow the authors to conclude that CD patients 
with symptomatic stenosis could be treated with IFX, they 
do suggest the possibility that IFX can be used to prevent 
the onset of ﬁ  brosis in patients not presenting a previous 
history of obstruction, or when the intestinal stenosis in CD 
results from a prevalent inﬂ  ammatory component rather than 
a ﬁ  brotic one.
Conclusions
The results of years of intensive research aimed at a better 
understanding of the pathobiology of CD led to a new 
approach in the management of patients unresponsive/intol-
erant to standard therapies such as steroids and/or immuno-
suppressors. Biologic compounds have been developed in 
order to target speciﬁ  c molecules and/or pathways involved 
in CD pathogenesis. TNF-α is likely to be a key mediator in 
the inﬂ  ammatory cascade playing a central role in mucosal 
inﬂ  ammation, so, based on this rationale, antagonizing this 
cytokine has brought a dramatic change both in the patient’s 
and the physician’s perspective of CD treatment. IFX, the 
ﬁ  rst anti-TNF biologic agent approved for the treatment of 
CD, has been demonstrated to be effective both in induc-
ing and maintaining clinical remission for at least 1 year 
(based on clinical trial data).22–25 These ﬁ  ndings have been 
conﬁ  rmed even in the pediatric population. Indeed, Hyams 
et al evaluated the efﬁ  cacy of maintenance treatment with 
IFX in children with CD, demonstrating that the scheduled 
administration of IFX every 8 weeks is able to keep the dis-
ease in remission for the long term.25 At 1 year follow-up, 
remission rate was 55.8%. Although no controlled study Biologics: Targets & Therapy 2009:3 47
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data are available on the use of IFX in CD beyond 1 year, 
a growing body of evidence from IFX and other anti-TNF 
clinical studies appears to indicate the efﬁ  cacy of long-term 
treatment as a disease-control strategy. After a decade of 
successful IFX treatment in CD patients, evolving evidence 
has offered some clues on the management of this drug in this 
setting. It appears evident that an induction regimen followed 
by scheduled maintenance treatment is superior to an on-
demand strategy in order to obtain greater clinical beneﬁ  t and 
long-lasting clinical remission which, in turn, may modify 
the long-term course of the disease. In addition, clinicians are 
focusing on new treatment strategies aimed at modulating 
the natural course of CD by using IFX at an early stage of 
the disease, before the disease itself has induced irreversible 
damage. Indeed, in rheumatoid arthritis, early interven-
tion with combined immunosuppression (anti-TNF-α plus 
immunosuppressants) has been shown to prevent progres-
sive joint destruction and improve long-term functional 
outcomes.46–48 In CD, preliminary data from a clinical trial 
evaluating this early aggressive therapeutic approach showed 
that combined immunosuppression (IFX plus AZA) was 
more effective than conventional management (corticoste-
roids) in the induction of remission, reduction of corticoste-
roid use and in achieving mucosal healing.33,34 Moreover, 
patients who received early combined immunosuppression 
were much more likely to maintain mucosal healing after 
2 years of treatment.34 Mucosal healing has now become a 
major goal of medical treatment in CD. Indeed, it was the 
objective of a sub-analysis of the ACCENT I study.36 In this 
trial, no patients showing endoscopic response to IFX therapy 
required hospitalization compared to 28% of those patients 
not achieving mucosal healing. Therefore, these results, 
together with those of Schnitzler et al support the evidence 
that IFX could substantially reduce patient-care costs for 
these patients and, hopefully, change the natural course 
of CD.37 Multiple clinical trials have shown that development 
of ATI is an important epiphenomenon of IFX treatment.39–42 
In fact, ATI have been correlated with infusion reactions and 
loss of response.39,40 Various strategies have been studied in 
order to decrease ATI formation, but only systematic treat-
ment, consisting of induction and scheduled maintenance, 
has proven effective in reducing ATI levels.40,41 The con-
comitant use of immunosuppressants and IFX administration 
has led to conﬂ  icting results about ATI formation. Another 
issue regarding the use of IFX in CD is whether there is a 
cause–effect relationship between IFX and intestinal stric-
tures or whether it can be used in their presence. On this 
issue, although the paper by Lichtenstein et al showed that 
treatment with IFX does not appear to increase the risk of 
stricture development in patients with CD, these authors 
suggested that the use of IFX should be avoided in patients 
with obstructive symptoms or presenting a stricture, with a 
bowel retro-dilation.45 Despite substantial clinical evidence 
that IFX treatment may play a major role in the therapeutic 
algorithm in CD, some concerns about its long-term use 
remain. Safety concerns associated with long-term use of 
IFX, or the high cost of scheduled maintenance treatment, 
or possibly both, have led physicians to become reluctant to 
use this compound.49,50 To maximize treatment efﬁ  cacy and 
minimize side effects, prospective studies aimed at predict-
ing subgroups of patients who will develop an aggressive 
disease course (eg, young age at diagnosis [ 40 years], 
perianal disease, need of systemic steroids at ﬁ  rst presenta-
tion) are mandatory in order to identify those CD patients 
who would beneﬁ  t from an early and aggressive treatment 
strategy with biologic agents.51 Assigning these agents in 
the correct context for CD patients has become the future 
challenge for the clinician.
Abbreviations
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